Showing 2631 results
- https://www.novartis.com/news/media-releases/sandoz-regulatory-submission-proposed-biosimilar-adalimumab-accepted-fdaAdalimumab is an anti-TNF medicine used to treat a range of immunological diseases[1] The comprehensive data package provided is expected to demonstrate that Sandoz proposed biosimilar adalimumab…
- https://www.novartis.com/news/media-releases/novartis-and-amgen-announce-expanded-collaboration-banner-alzheimers-institute-pioneering-prevention-programParties to collaborate on a new Generation Study 2, assessing whether investigational drug CNP520 can prevent or delay the symptoms of Alzheimer's disease (AD) Clinical trial is part of the…
- https://www.novartis.com/news/media-releases/novartis-presents-data-ash-patients-serious-blood-disorders-lymphoma-leukemia-and-sickle-cell-diseasePrimary results of pivotal KymriahTM Phase II JULIET study in relapsed/refractory DLBCL Post-hoc sub-analysis of crizanlizumab (SEG101, formerly SelG1) SUSTAIN trial evaluating time to…
- https://www.novartis.com/news/media-releases/novartis-submits-application-fda-kymriahtm-tisagenlecleucel-adult-patients-rr-dlbcl-seeking-second-indication-first-ever-fda-approved-car-t-therapySubmission based on updated analyses from global, multi-center Phase II JULIET study, which met primary endpoint, including 6-month data to be presented at ASH 2017 Kymriah has demonstrated…
- https://www.novartis.com/news/media-releases/novartis-present-first-its-kind-evidence-cosentyx-potential-maintain-mobility-patients-and-psaLong-term 4-year data in ankylosing spondylitis (AS) and 24-weeks data in psoriatic arthritis (PsA) to be presented at the 2017 ACR/ARHP Annual Meeting[1],[2] Structural disease progression is a…
- https://www.novartis.com/news/media-releases/novartis-announces-planned-acquisition-advanced-accelerator-applications-strengthen-oncology-portfolioNovartis to acquire Advanced Accelerator Applications pending outcome of tender offer and works council consultation Acquisition would add Lutathera®, a first-in-class RadioLigand Therapy (…
- https://www.novartis.com/news/media-releases/novartis-paradigms-data-show-children-and-adolescents-ms-had-82-lower-relapse-rate-gilenya-vs-interferon-beta-1aPARADIGMS data also show patients treated with Gilenya had significantly fewer new brain lesions vs. those on interferon beta-1a Currently there are no specifically approved disease…
- https://www.novartis.com/news/media-releases/sandoz-proposed-biosimilar-pegfilgrastim-accepted-ema-regulatory-reviewComprehensive data package demonstrates that Sandoz biosimilar pegfilgrastim matches the reference biologic in terms of safety, efficacy and quality Pegfilgrastim is a long-acting version of…
- https://www.novartis.com/news/media-releases/novartis-confirms-leadership-multiple-sclerosis-ms-scientific-advancements-and-new-data-presented-ectrimsFull data from the pivotal Phase III PARADIGMS study of Gilenya® (fingolimod) in pediatric MS will be presented for the first time With 54 accepted abstracts, Novartis presence spans from…
- https://www.novartis.com/news/media-releases/novartis-delivered-growth-top-and-bottom-line-all-divisions-q3Net sales grew 2% (cc[1], +2% USD), with growth in all divisions: Cosentyx (USD 556 million, +83% cc) showed strong growth across all indications Entresto (USD 128 million, +138% cc) grew…
Pagination
- ‹ Previous page
- 1
- 2
- 3
- 4
- 5
- 6
- 7
- …
- 264
- › Next page